FDA Expands Access to Investigational Drugs, Clarifies Charges

Washington Drug Letter
The FDA has revised its investigational new drug (IND) rules to expand access to such drugs for patients who are seriously ill or have life-threatening conditions and lack other treatment options, and to permit charging for the drugs in studies or expanded-access programs.

To View This Article:


Buy This Article Now

Add this article to your cart for $10.00